Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 8/20 | 0.81 |
| ▸ | CASP4 | P49662 | 2/20 | 0.81 |
| ▸ | CASP5 | P51878 | 2/20 | 0.81 |
| ▸ | CASP7 | P55210 | 2/20 | 0.81 |
| ▸ | CASP9 | P55211 | 2/20 | 0.81 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.81 |
| ▸ | CASP10 | Q92851 | 2/20 | 0.81 |
| ▸ | ELANE | P08246 | 2/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | IL1B | P01584 | 2/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | CASP2 | P42575 | 1/20 | 0.40 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.39 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.39 |
| ▸ | STAT6 | P42226 | 4/20 | 0.38 |
| ▸ | F2 | P00734 | 3/20 | 0.38 |
| ▸ | F10 | P00742 | 2/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.38 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.38 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vrt 043198 SCHEMBL20099210 | 1.00 | CASP1 (0.81) | CASP1CASP4CASP5CASP7CASP9 | |
| Vrt 043198 SCHEMBL13928446 | 1.00 | CASP1 (0.81) | CASP1CASP4CASP5CASP7CASP9 | |
| Vrt 043198 SCHEMBL8279029 | 1.00 | CASP1 (0.81) | CASP1CASP4CASP5CASP7CASP9 | |
| Vrt 043198 SCHEMBL30278640 | 1.00 | CASP1 (0.81) | CASP1CASP4CASP5CASP7CASP9 | |
| Vrt 043198 SCHEMBL17969594 | 1.00 | CASP1 (0.81) | CASP1CASP4CASP5CASP7CASP9 | |
| Vrt 043198 SCHEMBL20298437 | 1.00 | CASP1 (0.81) | CASP1CASP4CASP5CASP7CASP9 | |
| SCHEMBL16883406 | 0.94 | CASP1 (0.71) | CASP1CASP4CASP5CASP7CASP9 | |
| SCHEMBL13742740 | 0.94 | CASP1 (0.71) | CASP1CASP4CASP5CASP7CASP9 | |
| SCHEMBL3469978 | 0.90 | CASP1 (0.66) | CASP1CASP4CASP5CASP7CASP9 | |
| SCHEMBL15459247 | 0.90 | CASP1 (1.00) | CASP1CASP4CASP5CASP7CASP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11946053-B2 | Methods for overcoming glucocorticoid resistance and for determining glucocorticoid resistance potential in cancer | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| US-20230364054-A1 | METHODS FOR TREATING COVID-19 | MEDSTAR HEALTH, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230364054-A1 | METHODS FOR TREATING COVID-19 | MEDSTAR HEALTH, INC. | 2023-11-16 | — | — | US | disclosed |
| US-11654132-B2 | Methods for treating COVID-19 | MEDSTAR HEALTH, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-11654132-B2 | Methods for treating COVID-19 | MEDSTAR HEALTH, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| EP-3558335-B1 | CASPASE-1 INHIBITION AND USES THEREOF FOR PREVENTION AND TREATMENT OF NEUROLOGICAL CONDITIONS | CASP AID INC (CA) | 2023-04-19 | — | — | EP | disclosed |
| US-20220395488-A1 | METHODS FOR TREATING COVID-19 | MEDSTAR HEALTH, INC. | 2022-12-15 | — | — | US | disclosed |
| US-20220054454-A1 | CASPASE-1 INHIBITION AND USES THEREOF FOR PREVENTION AND TREATMENT OF NEUROLOGICAL CONDITIONS | CASP-AID INC. (CA) | 2022-02-24 | — | — | US | disclosed |
| US-11160788-B2 | Caspase-1 inhibition and uses thereof for prevention and treatment of neurological conditions | Leblanc, Andrea | 2021-11-02 | — | — | US | disclosed |
| US-20200102565-A1 | METHODS FOR OVERCOMING GLUCOCORTICOID RESISTANCE AND FOR DETERMINING GLUCOCORTICOID RESISTANCE POTENTIAL IN CANCER | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2020-04-02 | — | — | US | disclosed |
| US-7417029-B2 | Prodrug of an ice inhibitor | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-08-26 | — | — | US | disclosed |
| US-7417029-B2 | Prodrug of an ice inhibitor | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-08-26 | — | — | US | disclosed |
| US-7358273-B2 | Inhibitors of caspases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358273-B2 | Inhibitors of caspases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-04-15 | — | — | US | disclosed |
| WO-2005117846-A2 | ICE INHIBITORS FOR THE TREATMENT OF AUTOINFLAMMATORY DISEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005053665-A1 | TREATING INFECTIOUS DISEASES USING ICE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-06-16 | — | — | WO | disclosed |
| US-20030232986-A1 | Inhibitors of caspases | VERTEX PHARMACEUTICALS INCORPORATED | 2003-12-18 | — | — | US | disclosed |
| US-6531474-B1 | Treating inflammatory disease, osteoarthritis, glomerulonephritis, rheumatoid arthritis, psoriasis, graft vs. host disease, sepsis, or septic shock | VERTEX PHARMACEUTICALS INCORPORATED | 2003-03-11 | — | — | US | disclosed |
| EP-1064298-A2 | INHIBITORS OF CASPASES | Vertex Pharmaceuticals Incorporated (US) | 2001-01-03 | — | — | EP | disclosed |
| WO-1999047545-A2 | INHIBITORS OF CASPASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1999-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220395488-A1 | METHODS FOR TREATING COVID-19 | CASP1, IL1B, PYCARD | CASP1 1/4885CASP4 13/4885CASP5 31/4885 |
| US-20220054454-A1 | CASPASE-1 INHIBITION AND USES THEREOF FOR PREVENTION AND TREATMENT OF NEUROLOGICAL CONDITIONS | CASP1, CASP5, CASP10 | CASP1 1/4885CASP4 7/4885CASP5 2/4885 |
| US-20230364054-A1 | METHODS FOR TREATING COVID-19 | CASP1, IL1B, PYCARD | CASP1 1/4885CASP4 13/4885CASP5 31/4885 |
| US-11160788-B2 | Caspase-1 inhibition and uses thereof for prevention and treatment of neurological conditions | CASP1, CASP5, CASP10 | CASP1 1/4885CASP4 7/4885CASP5 2/4885 |
| US-20030232986-A1 | Inhibitors of caspases | CASP1, APAF1, IRF3 | CASP1 1/4885CASP4 11/4885CASP5 4/4885 |
| US-11654132-B2 | Methods for treating COVID-19 | CASP1, IL1B, PYCARD | CASP1 1/4885CASP4 13/4885CASP5 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.